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VIII. Connective Tissue Diseases and Aging 
1. AGING AND THE BIOLOGY OF CONNECTIVE 
TISSUE 
Aging is a universal process affecting man in a predictable 
and unavoidable manner. Although most of the basic mecha-
nisms of the aging process are not known, several theories have 
been proposed. Since connective tissues playa crucial role in 
maintaining the normal physiological functions of human or-
gans, it is clear that changes in the biochemistry of connective 
tissue components can result in age-related degenerative proc-
ess_ For example, it has been clearly shown that there are 
definite changes in the amount and composition of collagen in 
most organs. In particular, fibrotic processes characterized by 
increased collagen deposition in several internal organs, such as 
liver and aorta, can lead to functional incapacity of these tissues. 
On t he other hand, degeneration of the elastic fibers in vascular 
connective tissues in arteriosclerosis at least partly explains the 
clini cal manifestations of this condition. 
The metabolic capacity and life-span of fibroblasts and other 
cells in human tissues may be determinates in aging. Studies 
have demonstrated that certain cells have only a limited life-
span when maintained in tissue culture and that cells taken 
from older people have a shorter life-span than the cells ob-
tained from infants. The synthesizing capacity of cells, for 
example, the production of connective tissue components by 
fibro blasts, appears to decrease with age. 
The age-related processes mentioned above can be initiated 
and hastened by environmental factors. Of particular concern 
is actinic damage to the skin in aging. Exposure to sunlight and 
other traumatizing factors causes degenerative changes in the 
connective tissue components and nota bly contributes to wrin-
kling and premature aging of the skin. On the cellular level, the 
actinic damage contributes to derangement of the genetic ma-
terial and perturbs the control mechanisms of t he cell growth. 
As a consequence, the incidence of several skin tumors, such as 
basal cell carcinoma and malignant melanoma, is correlated 
with the degree of sun exposure. 
, Status of R esearch 
Collagen. Collagen is the major structural protein of the 
body _ In addition to its prominence and import in skin, it is 
responsible for major structural functions in all t issues of the 
body including, bone, tendon, ligament, cartilage, blood vessels, 
and heart valves. Recent work has shown that collagen is not 
a single molecule but a family of closely related molecules. Most 
tissues, including skin, contain several types of collagen; some 
• tissu es, such as bone and cartilage, contain predominantly a 
single type of collagen. Collagen molecules are very different 
from other proteins in the body. They consist of extremely long, 
thin rods with the extraordinary dimensions of 3,000 A by 15 
A. The molecule is composed of 3 individual polypeptide chains 
that intertwine much like the strands of a rope. This tightly 
( coiled structure renders the molecule impervious to the multi-
tud e of proteolytic enzymes that regularly invade tissue spaces. 
As the molecule is synthesized, it undergoes an orchestrated 
series of unique enzymatic reactions that are undoubtedly crit-
ical for function. In order for collagen to function maximally as 
the "structural steel" of connective tissue, the individual mol-
ecules must be joined in such a way as to prevent slippage. 
Collagen crosslin king has evolved as a unique series of covalent 
reactions not known to occur in other proteins and is essential 
to achieve maximal strength. Maximal crosslinking occurs only 
as the end result of several steps that begin in the cell: hydrox-
ylation of lysine, 2-stage glycosylation of hydroxy lysine, the 
processing of pro collagen in the extracellular space, fibril for-
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mation, and conversion of certain lysyl and hydroxylysyl resi-
dues to aldehydes. Only after all of these modifications have 
occurred can crosslinking take place normally. Defects in any 
stage of this cascade can result in abnormal crosslin king and 
weakened connective tissues. Since not only skin but all tissues 
of the body rely on connective tissue fo r structural stability, 
defective collagen biosynthesis results in disease in many organ 
systems. Common manifestations in the skin are fragility, poor 
wound healing, and wrinkling. Other manifestations are skeletal 
deformity and easily broken bones, hypermobile joints that 
easily dislocate and become arthritic, eye disease, such as 
dislocated lenses and keratoconus, abnormal blood vessels in-
cluding accelerated arteriosclerosis and aneurysm formation, 
prolapsing heart valves that may result in heart failure, emphy-
sema, hernias, and diverticula of internal stru(:tures. 
Since collagen constitutes the major structural protein of t he 
body, mechanisms for mediating its orderly restructuring must 
be present. Because of the extraordinary resistance of collagen 
to degradation by most proteases, specific enzymes are required 
for the initiation of collagen breakdown. Stringent regulatory 
mechanisms for the control of these collagenases, and therefore, 
of collagen degradation in general, must exist so that anomalous 
patterns of collagen breakdown or accumulation do not occur. 
Elastic fibers. The elastic connective tissue fibers are highly 
branching structures whose presence in various connective t is-
sues is responsible for physiologic elasticity of the organs. The 
elastic fibers are most notably present in the aorta and other 
vascular connective tissues. They are also abundant in various 
tendons, such as ligamentum nuchae and the achilles tendon; 
and in the lungs. In normal human skin, the elastic connective 
tissue proteins are only a relatively small fraction of the total 
dermal proteins, collagen being the predominant component. 
Electron microscopic examination of elastic connective tis-
sues has demonstrated that elastic fibers in the body consist of 
2 distinct components. The major component has an amor-
phous appearance, demonstrates no distinct periodicity, and 
represents biochemically the elastin protein. T his amorphous 
elastin component is surrounded by distinct fibrillar structures 
that have a regular diameter of 10-12 nm. T hey are the so-
called elastic fiber microfibrillar protein. These 2 proteins, the 
elastic and the microfibrillar protein, exist in close association 
in various connective t issues. 
The fibers composed of elastin, when visualized by light or 
electron microscopic techniques, appear as amorphous, branch-
ing structmes that, in certain connective tissues, form continu-
ous sheets. T he basic molecular unit of elastin is a linear 
polypeptide with an approximate molecular weight of 72,000 
daltons. 
Elastin has a highly characteristic amino acid composition in 
t hat it is relatively rich in valine and alanine and lacks trypto-
phan, cystine, and methionine. About one third of the total 
number of amino acid residues is glycine. Studies on the amino 
acid sequence show that glycine residues in elastin are randomly 
distributed along the polypeptide chain, unlike the even distri-
bution in the typical collagen sequence. Instead, mul t iple se-
quences, such as lys-ala-ala-lys and lys-ala-ala-ala-Iys, appear 
repeatedly in the molecule. Although elastin also contains some 
hydroxyproline, it is less plentiful than in collagen, and the 
amount is variable. Elastin appears to contain no hydroxylysine 
or sugar residues covalently linked to the polypeptide cham. 
Crosslinks that covalently bind elastin polypeptide chains 
into a fiber network are characteristic features of elastic fibers. 
The 2 major crosslink compounds, desmosine and its isomer, 
isodesmosine, appear to be unique to elastin. 
1' he ini t ial steps in the formation of desmosines have some 
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similarit ies to those in the crosslin king of collagen. After the 
newly-synthesized elastin polypeptides have been transported 
out of the cells into the extracellular space, the polypeptides 
undergo chemical modifications, such as the oxidative deami-
nation of certain lysyl residues to form reactive aldehyde deriv-
atives. The desmosine compounds are created by the fusion of 
4 lysine-derived residues that form a highly stable covalent 
crosslink. Three of the residues are aldehydes derived from 
lysines, and the fourth is unmodified lysine in the polypeptide 
chain. These 4 residues are brought into juxtaposition, presum-
ably by folding and alignment of the polypeptides, in such a 
way that a spontaneous condensation results in the formation 
of desmosine. 
The rust step in the crosslinking process, the oxidative deam-
ination of lysyl residues to form aldehydes, is catalyzed by lysyl 
oxidase. Abnormal crossiinking of elastin is partly responsible 
for the clinical manifestations of diseases in which there is a 
genetic deficiency or reduced activity of Iysyl oxidase. Deficient 
Iysyl oxidase activities have been encountered, for example, in 
an inbred strain of mice demonstrating aortic aneurysms, re-
duced tensile strength of skin, and bone abnormalities. An 
analogous situation in man may be Ehlers-Danlos syndrome 
type V, in which a deficiency of Iysyl oxidase has been sug-
gested. Menkes kinky hair syndrome, a disease characterized 
by defective membrane transport of copper, demonstrates con-
nective tissue abnormalities that are probably explained by 
decreased lysyl oxidase activity due to abnormally low copper 
concentrations of the extracellular milieu. 
The intracellular biosynthesis of elastin polypeptides follows 
the same basic principles as the formation of other mammalian 
proteins. Elastin appears to be synthesized by connective tissue 
cells, and the translation of the messenger-RNA-molecules 
coding for elastin polypeptides takes place in the rough endo-
plasmic reticulum of these cells. After translation, the newly 
synthesized polypeptides are fed into the disternae of the rough 
endoplasmic reticulum in a manner similar to that which takes 
place during the biosynthesis of collagen and other proteins 
destined for export from the cell. The polypeptides are then 
transferred from the rough endoplasmic reticulum into the 
extracellular space packaged in Golgi vacuoles or related vesi-
cles. 
Even though the metabolic turnover of connective tissues, 
and in particular elastin, in adult animals may be relatively 
slow, there is normally a continuous degradation of small 
amounts of elastin. Following the initial isolation of a specific 
elastase from pancreatic tissues, several other elastolytic en-
zymes were reported in other tissues, and in leukocytes, mac-
rophages, and platelets. Of particular interest is the elastase 
found in human leukocytes because the release of this enzyme, 
together with other lysosomal proteolytic enzymes, probably 
contributes to the damage of blood vessels in diseases such as 
leukocytoclastic vasculitis. The elastases may play a role in 
other disease processes, such as arteriosclerosis, pulmonary 
emphysema, and the invasion of various tumors into the adja-
cent connective tissues. Furthermore, a specific elastolytic ac-
tivity in aorta tissue has been shown to increase with advancing 
age, thus suggesting that aging and degenerative changes of the 
cardiovascular system might be partly explained by an in-
creased rate of degradation of the elastic fibers. 
In general, elastases degrade elastin in neutral or slightly 
alkaline pH. The elastases are serine proteases and they appear 
to be inactivated by serum inhibitors, such as I-antitrypsin and 
2-macroglobulin. Analyses of the aminoterminal amino acids in 
the digestion products have indicated that the elastases pref-
erentially cleave the peptide bonds adjacent to glycine, alanine, 
and valine, the smallest amino acids found in nature. 
As indicated above, elastic fibers contain microfibrils that 
consist of a distinct protein, so-called elastic fiber microfibrillar 
protein. Biochemical characterization of the microfibrillar pro-
tein has demonstrated that its amino acid composition has no 
resemblance to that of elastin. In particular, it is re latively rich 
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in amino acids that are present only in small amounts or are 
entirely lacking in elastin: cystine, methionine, and histidine. 
On the other hand it contains less glycine, alanine, and valine 
than elastin, and it does not contain hydroxyproline. The con-
tent of cystine in the microfibrillar protein is particularly high, 
70-80 residues per 1000 amino acids. The microfibrils also 
contain a large number of sugar residues, such as hexose and 
hexosamine moieties, suggesting that the elastic microfibrillar 
protein is a glycoprotein. At this point, however, it is not clear 
whether the microfibrillar protein is a single type of glycopro-
tein or a family of related molecules. 
Ground substance. In addition to collagen and elastic tissue 
the skin connective tissues contain a ground substance of pro~ 
teoglycans (or mucopolysaccharides). Although these proteo-
glycans appear to be similar in many respects to those of other 
connective tissues, they have certain characteristics that are 
clearly different. Many of the differences have not been well 
delineated since only a portion of the skin proteoglycan struc-
tures has been determined. 
Proteoglycans have 2 major components. The rust of these is 
a polysaccharide chain containing disaccharide repeating units. 
The nature of these disaccharide repeating units has been the 
criterion by which each of the proteoglycans has been named. 
Thus, the disaccharide repeating unit for hyaluronic acid, chon-
droitin sulfate, dermatan sulfate, heparin sulfate and heparin 
differ in one or more ways. All of the skin proteoglycans contain 
uronic acid that gives them a negative charge. In addition, these 
molecules (with the exception of hyaluronic acid) have variable 
amounts of sulfate that provide an even stronger negative 
charge. 
The polysaccharide chains (with the possible exception of 
hyaluronic acid) are attached to a protein core (the second 
component) to form a proteoglycan. The attachment is usually 
through a specific oligosaccharide of galactose-galactose-xylose 
to the hydroxyl of serine. Most investigations of proteoglycan 
structure have been carried out on proteoglycans of cartilage; 
there has been little investigation of skin proteoglycans. There-
fore, presumed structures in skin have been extrapolated from 
the known structures in cartilage. 
Cartilage proteoglycan molecules have a molecular weight of 
approximately 1-2 million daltons. They gather around a hy-
aluronic acid core to form aggregates with molecular weights of 
as much as 100 million Daltons. One or more specific glycopro-
tein molecules have been implicated in the binding region 
between the proteoglycan and the hyaluronic acid core. The 
structure of the protein core of cartilage proteoglycan is essen-
tially undetermined. 
Cartilage is such a highly specialized connective tissue that 
there is no reason to believe that the extrapolated knowledge of 
its structure can actually apply to that of skin. It is not known 
whether skin proteoglycans form aggregates. Cartilage does not 
contain dermatan sulfate; skin does. Cartilage has keratan 
sulfate; skin does not. Skin contains heparin sulfate in large 
amounts; cartilage does not. Finally, skin contains mast cells, 
which, in turn, contain heparin. 
Biosynthesis of proteoglycans has not been completely de-
fined. The precursor molecules for synthesis of the polysaccha-
ride 'chains have been examined in skin and cartilage. The 
overall .assembly pattern of the protein core, followed by poly-
saccharide synthesis and the mechanisms of extrusion from the 
cells, and formation of aggregates are still unknown. Most of 
the biosynthetic work has been performed with cartilage pro-
teoglycans. It is likely that there are differences too in the 
biosynthesis of skin proteoglycans and cartilage proteoglycans. 
Degradation and turnover of proteoglycans have not been 
well demonstrated in any tissue. There are polysaccharide 
degrading enzymes in the skin. These enzymes will degrade 
only hyaluronic acid and chondroitin sulfate. They have no 
effect on heparin sulfate, dermatan sulfate, or heparin. Pro-
teases that degrade the protein core of a proteoglycan have 
been demonstrated in cartilage but not in skin. Thus it is not 
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known whether skin proteoglycans turn over as an entire mol-
ecule or whether only portions are degraded with subsequent 
excretion of other portions intact. Skin fibroblasts in culture are 
known to be capable of degrading the polysaccharide (glycos-
aminoglycan) portion of the proteoglycans. Moreover, inability 
of skin fibroblasts in culture to degrade proteoglycans has been 
used to diagnose proteoglycan storage diseases (mucopolysac-
charidoses). In these diseases there is accumulation of the 
polysaccharide portion of proteoglycans in many cells leading, 
in some syndromes, to severe deformity and death. Skin biop-
sies have been utilized to provide cells in culture that reflect 
the condition of cells elsewhere in the intact patient. 
The functions of the proteoglycans in skin are probably 
similar to those in cartilage. Thus, one would expect that a 
large "domain" would be controlled by these molecules. Water, 
as much as 1,000 times the volume of the proteoglycan itself, 
might be contained within each molecule. In this "domain" 
small molecules, such as salts, move freely but larger molecules, 
such as proteins, are excluded by the nature of the highly 
charged polysaccharide chains. The polysaccharides also serve 
as ion exchangers. Positively charged ions are bound to the 
negatively charged sulfate groups and, in turn, can be exchanged 
for other positively charged ions. This function of proteoglycans 
is related to calcification of bone. An ion exchange function in 
skin is yet to be demonstrated. The proteoglycan molecules 
also act as filters to keep out large molecules. Finally, there is 
evidence that the negatively charged molecules interact with 
cells to direct them in migration, growth, differentiation, etc. 
Proteoglycans are found in cells as well as in matrix ground 
substance. Most, if not all, cells contain heparin sulfate on their 
cell surface. Heparin sulfate has been shown directly on skin 
fibroblasts grown in culture. Small amounts of other proteogly-
cans, such as chondroitin sulfate and even dermatan sulfate, are 
components of some cells. The structure and function of these 
proteoglycans in the cells are not fully described. To date only 
the polysaccharide portions have been characterized and it can 
only be presumed that the intact molecules are similar to the 
proteoglycans of matrix. 
A special case is that of heparin. It is found exclusively in the 
granules of mast cells. Only some of the structural characteris-
tics of the polysaccharide portion have been determined. A 
proteoglycan of heparin found in rat skin has a protein core 
that is resistant to all proteolytic enzymes. Similar structures 
have not been described in man, probably because they have 
not been looked for. The function of heparin is open to specu-
lation. Would not one expect this molecule, the most highly 
charged molecule in the human body, to be very potent? It acts 
as an anticoagulant and as a lipid clearing factor. Neither of 
these functions is known for certain to be of physiological 
importance. 
Needs for Additional Research 
It is evident that aging presents a complex situation where 
multiple factors modify the connective tissues and other com-
ponents of skin. In order to understand these processes in more 
precise terms, there is need for additional basic research to 
establish the biochemical and morphological features of con-
nective tissue. In particular, understanding of the interactions 
of various connective tissue components, such as collagen, 
elastin, and mucopolysaccharides, requires investigation. The 
knowledge derived from these studies can then be applied to 
age-related degenerative processes not only in skin but also in 
other tissues. 
Collagen. Although a great deal of information is accumulat-
ing concerning the structure of collagen in the skin, very little 
is known about the orchestration of the multiple steps which 
lead to the final product. An understanding of the fine control 
of synthesis and degradation in the skin might enable us to 
better control those conditions examined throughout this por-
tion of the report: aging, wound healing, fibrosis, tumor invasion 
and other inflammatory disorders. Regulation of type-specific 
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collagen synthesis, regulation of each of the enzymatic steps 
involved in posttranslational modification, regulation of colla-
gen degradation, and interactions of collagen with ground sub-
stance, elastin, and cells need to be examined comprehensively 
in skin fibroblasts and tissue. 
Elastic fibers . Although progress has been made in deline-
ating the molecular structure of elastin and microfibrillar pro-
tein, many details are yet to be clarified. Limited solubility 
frustrated early attempts. Now techniques are available to 
isolate each of these proteins so that primary structures can be 
determined. How synthesis and degradation of these proteins 
proceed needs to be determined, and this can be done best in 
cell culture systems. An understanding of normal biosynthesis 
will enable us to investigate the perturbations in elastic tissue 
associated with disease. 
Ground substance. Future research in skin proteoglycans 
should be directed toward basic structure and function. It is 
necessaJ'y to know whether the proteoglycans of skin are similar 
in structure to those of cartilage; whether proteoglycan aggre-
gates are formed; whether the protein cores of the various 
proteoglycans are similar to each other or totally different for 
the chondroitin sulfates, derma tan sulfate, and heparin sulfate. 
Knowledge of the structure of these proteoglycans is basic to 
effective examination of proteoglycan-collagen interaction and 
proteoglycan-cell interaction. The interaction of cellular and 
surface proteoglycans with other substances richly deserves 
exploration. Once the fundamental questions of structure are 
answered, a directed and logical approach can be made to major 
questions regarding changes of proteoglycan metabolism in 
wound healing, fibrosis, aging, inborn metabolic errors, and 
other pathological conditions. Knowledge of the structure and 
function of these molecules in skin contributes not alone to the 
understanding of diseases relating to skin; it may have a wider 
application. The ready availability of skin for biopsy and sub-
sequent tissue culture makes skin an ideal organ for basic study · 
of proteoglycan metabolism and interaction in all tissues of the 
body. 
2. FIBROSIS 
Fibrosis is a term introduced by pathologists to imply prolif-
eration of connective tissue, mostly collagen, at the microscopic 
level. An increase in collagen synthesis can be a useful event in 
embryonic development and wound healing. However, exces-
sive collagen deposition, secondary to many disease processes, 
may have a deleterious effect. Since any organ can be affected 
by fibrosis, it is difficult to estimate its prevalence. It is generally 
agreed, however, that it is a major problem in medicine. Fibrosis 
may follow infections, surgical incisions (abnormal scarring), 
physical and chemical trauma, immune responses, atheroscle-
rosis, and tumors. In fibrosis, collagen replaces functional tis-
sues, interferes with blood supply, and often leads to organ 
insufficiency and death. At present, there is no effective treat-
ment that can prevent or delay the progression of fibrosis. 
Status of Research 
Very little is known about how fibroblasts are activated to 
synthesize collagen. However, regardless of the primary cause, 
some organs respond to injury that eventually leads to fibrosis 
by a similar sequence of events. This type of response has been 
studied in skin (hypertrophic scars, keloids, scleroderma) , lung, 
(idiopathic pulmonary fibrosis and fibrosis secondary to colla-
gen-vascular disease and infections), liver cirrhosis (biliary cir-
rhosis and experimental cirrhosis), and atherosclerosis. Analysis 
of the data from these studies suggests that fibrosis involves at 
least 3 biological responses (a) a cellular reaction, (b) an im-
mune response, and (c) an increase in collagen types. 
Cellular infiltrates, mostly lymphocytes, plasma cells, and 
macrophages are the early event in fibrosis. These cells proba-
bly participate in activating the fibroblasts that are responsible 
for the collagen deposition. Immunofluorescence microscopy of 
specific anti collagen antibodies has shown that cellular infll-
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trates are accompanied by deposition of Type III collagen. 
Apparently then cellular inflltrates and Type III collagen dep-
osition precede the final stage of fibrosis, when Type I collagen 
deposition seems to be the predominant feature . 
Nonspecific circulating antibodies have been demonstrated 
in various diseases that eventually terminate in severe fibrosis 
(antinuclear antibodies, antismooth muscle antibodies, antimi-
tochondrial antibodies, rheumatoid factor, etc.). More recently, 
cell mediated immunity against collagen has also been demon-
strated. Lymphocytes from patients with idiopathic pulmonary 
fibrosis and scleroderma release migration inhibitory factor 
(MIF) and human monocyte chemotactic factor, respectively, 
when exposed to Type I collagen. Also, scleroderma lympho-
cytes release MIF when exposed to skin extracts from normal 
or scleroderma skin. This suggests that sensitized lymphocytes, 
probably involving Band T cells, take part in the regulatory 
mechanism of fibroblast activation. 
The final stage of fibrosis is characterized by replacement of 
functional parenchyma and blood vessels by collagen. In certain 
disorders, such as keloids and biliary cirrhosis, there is an actual 
increase in collagen concentration. In other disorders the 
amount of collagen per unit weight may remain unaltered, the 
basic change being an increase of Type I collagen and a pro-
portional reduction of Type III collagen. This change in distri-
bution of collagen types has been observed in scleroderma, 
atherosclerosis, and idiopathic pulmonary fibrosis. 
Needs for Additional Research 
During the past 10 years there has been an explosion of 
knowledge in the structure and metabolism of collagen. This 
new information has opened various avenues for basic and 
clinical research in the field of fibrosis. The skin, uniquely 
accessable, is the logical system to use for the study of fibrosis 
in both human and animal experimental models. 
Since the early event in fibrosis involves tissue lymphocytes, 
it would be of considerable value to determine what role, if any, 
these cells play in the control mechanism of collagen synthesis 
by fibroblasts. Lymphocytes from scleroderma, biliary cirrhosis 
and idiopathic pulmonary fibrosis should be tested for produc-
tion of lymphokines that may promote collagen synthesis. Lym-
phocytes from various fibrotic disorders should also be tested 
for delayed hypersensitivity responses with antigens obtained 
from fibrotic tissues. Such antigens should include Type I and 
Type III collagens. Delayed hypersensitivity could be assessed 
by measuring blast-transformation, lymphokines, and chemo-
tactic factors production. 
Metabolic studies should be pursued in vitro on fibroblasts 
from fibrotic tissue in order to determine rate of collagen 
synthesis, distribution of collagen types, and levels of enzymes, 
all of which are important in connective tissue breakdown. 
Such fibroblasts should be obtained from both the early cellular 
and late fibrotic stages. Studies should be designed to determine 
possible interactions of Type I and Type III collagens, since 
current data suggests that Type III collagen is deposited in the 
early stage and Type I collagen in the final stage in various 
fibrotic diseases, such as scleroderma, keloids, and liver cirrho-
sis; a similar sequence of events has been demonstrated follow-
ing acute and chronic inflammation induced in experimental 
animals. 
On the basis of current knowledge about the pathophysiology 
of fibrosis, therapy could be developed (a) to control the cellu-
lar-immune response, (b) to reduce collagen synthesis, and (c) 
to promote collagen breakdown. 
Since the early event in fibrosis appears to be a cellular-
immune response, its control may prevent the final stage of 
collagen deposition. Research protocols with immunosuppres-
sive agents should be designed to treat the early stage of 
fibrosis. Control of the cellular-immune response appears, at 
present, to be the most practicable approach to the treatment 
of fibrosis. 
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Proline analogs, e.g., cis-hydroxyproline, are incorporated in 
the collagen molecule and interfere with molecular structure in 
such a way that the collagen produced is more susceptible to 
degradation. Cis-hydroxyproline can reduce tensile strength in 
scars; unfortunately, it is too toxic for human clinical trials. 
Nevertheless, analogs of proline and, perhaps, lysine should be 
tested in experimental animals for their potential role in the 
control of fibrosis. Theoretically, compounds that inhibit col-
lagen crosslinkage could permit the synthesis of structurally 
normal collagen and prevent its polymerization into fibers. 
Beta-aminopropionitrile is such a compound. It, however 
proved to be unsuccessful in clinical trials on scleroderm~ 
patients. Crosslinkage of collagen can also be modilled by 
penicillamine, which is currently being evaluated in the treat-
ment of scleroderma and rheumatoid arthritis. Compounds 
with structures similar to beta-amino-propionitrile and perucil-
lamine should be developed and tested experimentally for po-
tential use in fibrotic states. The development of fibrosis may 
be due to a reduction in collagen breakdown. If so, compounds 
that increase collagenase activity may prove to be useful in the 
treatment of fibrosis. 
3. INHERITED COLLAGEN DISORDERS 
Inherited disorders of connective tissue affecting the skin are 
common genetic diseases. Their treatment makes large de-
mands on financial and personnel resources, mainly in rehabi-
litative hospitals that deal with skeletal problems resulting from 
structural defects. Diseases, such as Marfan's disease, Ehlers-
Danlos syndrome, cutis laxa, and osteogenesis imperfecta are 
known Or thought to result from a primary defect in collagen 
biosynthesis. Other connective tissue disorders, such as homo-
cystinuria and alkaptonuria, are secondary to the abnormal 
accumulation of metabolites caused by a primary enzymatic 
defect. 
Status of Research 
In recent years, careful clinical studies have helped to char-
acterize the heterogeneity in these conditions. In most of these 
disorders, autosomal dominant, autosomal recessive, and sex-
linked forms of the disorder have been recognized. Recently, a 
great deal of progress in the biochemical understanding of these 
disorders has been made. Evidence is now available that several 
of these clinical phenotypes may result from defective collagen 
biosynthesis. Forms of the Ehlers-Danlos syndrome have been 
recognized that arise from (1) defective lysyl hydroxylase activ-
ity, (2) defective pro collagen peptidase activity, and (3) defec-
tive synthesis of Type III collagen. Deficient synthesis of Type 
I collagen has been demonstrated in osteogenesis imperfecta. 
Other diseases affect collagen secondarily. Thus, abnormal ho-
mocysteine accumulation in homocystinuria results in defective 
crosslin king of collagen by modifying lysyl oxidase. 
Hydroxylysine is essential for collagen cross-linking. The 
enzyme lysyl hydroxylase is inhibited by homogentisic acid. In 
alkaptonuria, homogentisic acid accumulation gives rise to an 
oxidized black pigment that preferentially deposits in cartilage 
and leads to fragility of cartilageous joint structures and sub-
sequent inevitable crippling. 
The 2 inherited dermatologic conditions that demonstrate 
clearly derangement of elastic structures are pseudoxanthoma 
elasticum and cutis laxa. In the case of pseudo xanthoma elas-
ticum, the evidence is mainly morphologic. Electron micro-
scopic examination of the affected skin shows that the amor-
phous elastin component of the fibers has been replaced by 
bundles of granular material whose staining properties differ 
from those of normal elastin. These observations suggest that 
either the synthesis and crosslinking of elastin may be defective 
in this disease or increased degradation of elastin leads to 
destruction of functional elastic structures in affected tissues. 
The major histopathologic feature of cutis laxa has been 
defined as degeneration of the elastic fibers in the dermis. 
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Similar changes probably occur in other connective tissues. 
Electron microscopic examination of skin from 2 patients with 
cutis laxa, one with acquired and the other with a congenital 
fonn of the disease, has demonstrated that the elastic fibers are 
deficient in elastin, whereas the elastic rnicrofibrils appear 
nonnal. It was suggested, therefore, that a synthetic abnormal-
ity of elastin may be the underlying defect in cutis laxa. This 
was studied in 2 patients with X-linked recessive cutis laxa by 
assaying the activity of lysyl oxidase in cultures of their skin 
fibroblasts. The enzyme activity was markedly under that of 
controls when collage was used as a substrate. Decreased activ-
ity, although to a lesser degree, was also observed when elastin 
was used as a substrate. On the basis of these observations, we 
can hypothesize that the defect in some patients with cutis laxa 
may be decreased crosslin king of both elastin and collagen, thus 
leading to generalized connective tissue weakness. 
An understanding of the biochemical nature of some of these 
disorders has provided clues for therapy. One patient with 
hydroxylysine deficiency associated with abnormal lysyl hy-
droxylase has improved with ascorbic acid. Since ascorbic acid 
is capable of reversing lysyl hydroxylase inhibition by homo-
gentisic acid, it might be an effective therapy in alkaptonuria. 
Of course, the best way to deal with diseases that are inher-
ited in a simple Mendelian fashion is to prevent their occur-
rence; this can come about only with exact genetic understand-
ing coupled, whenever possible, with identification of abnormal 
genes in clinically normal carriers. 
Inherited disorders of connective tissue are clinically heter-
ogeneous. Clinical genetic studies have recently identified sev-
eral familial subgroups within most of these disorders. Seven 
subtypes of Ehlers-Danlos syndrome, for example, are currently 
recognized. This work is just beginning and, in the case of rare 
disorders, will certainly require an interinstitutional collabora-
tive effect. In clinical trials samples for fibroblast culture should 
be sent to central banks along with a careful clinical character-
ization of the patient, thus making cells available to all inves-
tigators. From exact biochemical understanding of the nature 
of genetic disease will come our best opportunity to identify 
and categorize the disorders, to provide accurate genetic advice 
and diagnosis, and to design appropriate therapy. These unu-
sual experiments of nature by their very aberrations provide us 
with unique opportunities to gain an understanding of the 
nature of normal as well as diseased connective tissue and to 
correlate structure-function relationships. 
Since collagen is a predominant product of skin fibroblasts 
they are a natural source to use for study of collagen biosyn-
thesis and detection of defects in collagen biosynthesis. Tech-
niques are available for the measurement and characterization 
of collagens synthesized by fibroblasts and the modifying en-
zymes necessary for collagen biosynthesis. Efforts should be 
made to study the regulation of collagen synthesis in skin 
fibroblasts taken from both normal subjects and patients with 
inherited connective tissue disorders. 
4 . WOUND HEALING AND KELOID FORMATION 
Wound healing in normal skin is a complex process charac-
terized by an orderly sequence of events that involve the 
epidermis and the connective tissue. 
The remodeling of connective tissue during wound healing 
requires mechanisms not only for the formation but also for the 
regulated removal of extracellular structural elements. In ad-
dition, it must allow for cellular detachment, so that cell move-
ments may take place. In humans, for example, the epithelium 
at the wound edge becomes detached from its connective tissue 
base and migrates across the wound surface in an effort to "plug 
the hole." Repair of the connective tissue occurs concomitantly 
with that of the epidermis, so that there is an orderly restruc-
turing of tissue and an increase in tensile strength. 
This mechanism may be altered in some individuals resulting 
in the formation of unsightly hypertrophic scars and keloids. 
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The incidence of keloids is not exactly known although available 
figures suggest that 5 to 16% of the general population may be 
susceptible. Dark-skinned races have a greater propensity to 
develop hypertrophic scars or keloids than caucasians, as much 
as from 5:1 to 15:1. There appears to be a hereditary predispo-
sition that is transmitted as a simple mendelian dominant trait. 
Keloids are benign hyperplasias (overgrowths) of dermal 
connective tissue that develop following locally induced trauma, 
infection, or inflammation. Common factors are burns, surgical 
incisons, ear piercing, vaccination, etc. Keloids and hyper-
trophic scars occur most frequently on the upper trunk and 
may be the cause of serious disability or of horrendous disfig-
urement, particularly following severe burns. Abnormal scar-
ring may also interfere with joint mobility and function. 
The cause of hypertrophic scars or keloids is not known. 
However, during normal wound healing there appears to be an 
equilibrium between collagen synthesis and its degradation; in 
susceptible individuals the equilibrium is altered. This results 
in a large deposition of collagen and other connective tissue 
components. Furthermore, the architectural. arrangement of 
collagen in keloids is markedly distorted. Fibroblasts are re-
sponsible for the amount of collagen deposited during wound 
healing since these cells not only synthesize collagen but also 
contain the enzyme collagenase that is responsible for its break-
down. In keloids a paradoxical situation obtains: although col-
lagen synthesis increases, as measured by peptidyl proline 
hydroxylase activity, so does collagenase activity; although the 
activity of the enzyme lysyl oxidase (involved in collagen cross-
linking) is normal or elevated, crosslinking is poor. Glyconsa-
minoglycans, particularly chondroitin-4-sulfate, also increases. 
Recent studies showed that 3 phenotypically different fibro-
blasts populations can be obtained from skin. Their distribution 
varies depending on their origin: normal skin, normal scars, 
hypertrophic scars, or keloids. 
Needs for Additional Research 
Further research should be directed toward factors that 
control the metabolism and mitotic activity of fibroblasts and 
their responses to injury. New animal models for study of 
abnormal wound healing should be sought. Fibroblasts from 
early and late stages of hypertrophic scars and keloids should 
be cultured to determine the rate of collagen synthesis, the 
collagen-type distribution, and rates of hydroxylysine glycoside 
and collagen crosslink biosynthesis. Collagenase activity should 
be estimated during early and late stages in the formation of 
hypertrophic scars or keloic;ls. Research treatment protocols 
should be designed to test compounds that inhibit collagen 
synthesis and those that promote collagenolytic activity, as 
described in the section on fibrosis. Further studies should be 
performed to determine the exact mode of inheritance of keloids 
and to identify abnormal genes so that the predisposed individ-
uals can be detected earlier. 
5. SKIN DESTRUCTION BY CUTANEOUS TUMOR 
INVASION 
Skin cancers constitute the most common form of cancer in 
the world . Since t he skin is uniquely accessible to constant 
scrutiny, skin cancers are often detected quite soon after onset 
and, thus, can be treated promptly and appropriately. Conse-
quently skin cancers are the most curable forms of cancer 
known. Even so, knowledge of the mechanisms by which tumors 
invade tissues is in its infancy. 
It is known that proteolytic activity increases with malig-
nancy, therefore, it is logical to assume that the invasive prop-
erties of a variety of malignant tumors may depend in part 
upon proteases. A number of studies suggest that collagenase, 
the enzyme primarily responsible for initiating collagen break-
down, is increased in such human skin cancers a,s basal cell 
carcinoma, epidermoid carcinoma, and malignant melanoma. 
Cutaneous cancers, then, seem to be ideal prototypic tumors in 
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which to examine the mechanism by which tumors produce not 
only local tissue destruction and invasion but also metastatic 
disease. The urgency of such research is illustrated by patients 
with the hereditary disorder, xeroderma pigmentosum. These 
patients, who are afflicted with a profound genetic predisposi-
tion to skin cancer, experience cancer early in life. This situation 
follows an inexorably progressive course that ultimately leads 
to death. 
Needs for Additional Research 
Additional research must be carried out, not only upon the 
characteristics of cutaneous tumor cells themselves but also on 
the epithelial-stromal interaction that may well be quite im-
portant in the pathogenesis of tumor invasion. Although much 
attention has been directed toward the characteristics of cancer 
cells, very little has been paid to the properties of the stromal 
fibroblasts underlying the different types of malignant epithe-
lium. Alterations in the growth properties and in the function 
of stromal fibroblasts underlying skin cancers may be cardinal 
to the unraveling of the pathogenesis of cancer. 
Detailed studies of the nature of the proteolytic enzymes in 
cutaneous cancers must be carried out. The source of these 
enzymes that promote tumor invasion must be determined in 
an effort to establish whether they originate in tumor cells 
themselves or in the adjacent connective tissue stroma as part 
of a response to neoplasia. It is essential to study the factors 
that regulate both the growth of the cells and the production of 
various proteases so that their control might be attempted in 
the therapy ?f carcinoma. 
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